|
GB965637A
(en)
|
1962-04-23 |
1964-08-06 |
Tanabe Seiyaku Co |
L-ornithine l-aspartate
|
|
NL302572A
(https=)
|
1962-12-27 |
|
|
|
|
GB1067742A
(en)
|
1963-09-16 |
1967-05-03 |
Kyowa Hakko Kogyo Kk |
Process for the preparation of l-ornithine l-aspartate
|
|
ZA716628B
(en)
|
1970-10-15 |
1972-06-28 |
Richardson Merrell Spa |
Composition and method for treatment of hepatic disease and mental fatigue
|
|
FR2113774A1
(en)
|
1970-11-13 |
1972-06-30 |
Roques Ets |
Prepn of l-ornithine salts with org acids - using silver oxides
|
|
US4100293A
(en)
|
1974-04-15 |
1978-07-11 |
The Johns Hopkins University |
Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
|
|
US3950529A
(en)
|
1975-02-03 |
1976-04-13 |
Massachusetts General Hospital |
Amino acid formulations for patients with liver disease and method of using same
|
|
US4228099A
(en)
|
1978-03-17 |
1980-10-14 |
The Johns Hopkins University |
Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
|
|
US4320146A
(en)
|
1978-03-17 |
1982-03-16 |
The Johns Hopkins University |
Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
|
|
US4352814A
(en)
|
1979-04-18 |
1982-10-05 |
The Johns Hopkins University |
Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
|
|
US4284647A
(en)
|
1980-03-31 |
1981-08-18 |
The Johns Hopkins University |
Process for waste nitrogen removal
|
|
US4457942A
(en)
|
1982-08-20 |
1984-07-03 |
Brusilow Saul W |
Process for waste nitrogen removal
|
|
US4783443A
(en)
|
1986-03-03 |
1988-11-08 |
The University Of Chicago |
Amino acyl cephalosporin derivatives
|
|
US5139981A
(en)
|
1987-06-24 |
1992-08-18 |
Union Carbide Chemicals & Plastics Technology Corporation |
Process for preparing silver(I)-exchanged resins
|
|
US5591613A
(en)
|
1990-07-02 |
1997-01-07 |
Degussa Aktiengesellschaft |
Method for the preparation of D-arginine and L-ornithine
|
|
DE4020980C1
(https=)
|
1990-07-02 |
1991-09-26 |
Degussa Ag, 6000 Frankfurt, De |
|
|
JP3127484B2
(ja)
|
1991-02-28 |
2001-01-22 |
味の素株式会社 |
肝炎治療薬
|
|
US5767086A
(en)
|
1992-04-03 |
1998-06-16 |
Terrapin Technologies, Inc. |
Bone marrow stimulation by certain glutathione analogs
|
|
US5571783A
(en)
|
1993-03-09 |
1996-11-05 |
Clintec Nutrition Company |
Composition and method for treating patients with hepatic disease
|
|
JP3273578B2
(ja)
|
1993-09-21 |
2002-04-08 |
第一化学薬品株式会社 |
オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
|
|
US5840891A
(en)
|
1994-07-28 |
1998-11-24 |
Syntex (U.S.A.) Inc. |
2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
|
|
IL116674A
(en)
|
1995-01-09 |
2003-05-29 |
Mendell Co Inc Edward |
Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
|
|
WO1997030167A1
(en)
|
1996-02-13 |
1997-08-21 |
The Trustees Of The University Of Pennsylvania |
Method of treating liver disorders
|
|
ZA986614B
(en)
|
1997-07-25 |
1999-01-27 |
Gilead Sciences |
Nucleotide analog composition
|
|
GB9815567D0
(en)
|
1998-07-18 |
1998-09-16 |
Glaxo Group Ltd |
Antiviral compound
|
|
US6258849B1
(en)
|
1998-07-23 |
2001-07-10 |
Stanislaw R. Burzynski |
Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
|
|
CA2374273A1
(en)
|
1999-05-21 |
2000-11-30 |
Takeda Chemical Industries, Ltd. |
Liver function controlling agents
|
|
US6768024B1
(en)
|
2000-08-04 |
2004-07-27 |
Lion Bioscience Ag |
Triamine derivative melanocortin receptor ligands and methods of using same
|
|
JP3211824B1
(ja)
|
2000-10-26 |
2001-09-25 |
味の素株式会社 |
分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
|
|
JPWO2002074302A1
(ja)
|
2001-03-15 |
2005-07-14 |
独立行政法人理化学研究所 |
肝機能障害改善用アミノ酸組成物
|
|
US6503530B1
(en)
|
2001-11-01 |
2003-01-07 |
Chunghee Kimberly Kang |
Method of preventing development of severe metabolic derangement in inborn errors of metabolism
|
|
US20030105104A1
(en)
|
2001-11-27 |
2003-06-05 |
Burzynski Stanislaw R. |
Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
|
|
US20040229948A1
(en)
|
2002-04-12 |
2004-11-18 |
Summar Marshall L. |
Method for preventing hepatic encephalopathic episodes
|
|
US20030195255A1
(en)
|
2002-04-12 |
2003-10-16 |
Summar Marshall L. |
Method for treating hepatic encephalopathies
|
|
CN1383815A
(zh)
|
2002-05-08 |
2002-12-11 |
刘万忠 |
防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
|
|
US20040152784A1
(en)
|
2002-07-23 |
2004-08-05 |
Special Products Limited |
Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
|
|
JPWO2004019928A1
(ja)
|
2002-08-30 |
2005-12-15 |
味の素株式会社 |
肝疾患治療剤
|
|
US20050059150A1
(en)
|
2003-09-17 |
2005-03-17 |
Becton, Dickinson And Company |
Environments that maintain function of primary liver cells
|
|
MXPA03009902A
(es)
*
|
2003-10-29 |
2005-05-03 |
Manuel Francisco Lara Och Jose |
Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
|
|
CA2556752C
(en)
|
2004-02-23 |
2016-02-02 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
US7589235B2
(en)
|
2004-05-06 |
2009-09-15 |
Osteologix, A/S |
High yield and rapid synthesis methods for producing metallo-organic salts
|
|
WO2006059237A1
(en)
|
2004-08-30 |
2006-06-08 |
Lunamed, Inc. |
4-phenylbutyric acid controlled-release formulations for therapeutic use
|
|
SI2153870T1
(sl)
|
2004-11-26 |
2014-05-30 |
Ucl Business Plc |
Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
|
|
AU2015221466B2
(en)
*
|
2009-04-03 |
2017-02-02 |
Ocera Therapeutics, Inc. |
L-ornithine phenyl acetate and methods of making thereof
|
|
HUE035921T2
(en)
|
2009-04-03 |
2018-05-28 |
Ocera Therapeutics Inc |
L-ornithine phenyl acetate and methods of making thereof
|
|
CA2763894A1
(en)
|
2009-06-02 |
2011-01-13 |
Salix Pharmaceuticals, Ltd. |
Use of rifaximin to maintain remission of hepatic encephalopathy
|
|
CN104434894A
(zh)
|
2009-06-08 |
2015-03-25 |
Ucl商业有限公司 |
使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
|
|
AU2014250643B2
(en)
|
2009-06-08 |
2016-07-14 |
Ocera Therapeutics, Inc. |
Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
|
|
US8946473B2
(en)
*
|
2010-10-06 |
2015-02-03 |
Ocera Therapeutics, Inc. |
Methods of making L-ornithine phenyl acetate
|
|
CN102993037B
(zh)
*
|
2012-11-20 |
2015-03-04 |
南京工业大学 |
一种l-鸟氨酸苯乙酸盐的制备方法
|
|
PT2922576T
(pt)
|
2012-11-21 |
2018-01-24 |
Horizon Therapeutics Llc |
Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática
|
|
ES2769000T3
(es)
*
|
2014-11-24 |
2020-06-24 |
Ucl Business Ltd |
Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
|
|
CN107708684A
(zh)
|
2015-04-20 |
2018-02-16 |
欧塞拉治疗有限公司 |
L‑鸟氨酸苯乙酸盐制剂
|
|
WO2017031131A1
(en)
|
2015-08-18 |
2017-02-23 |
Ocera Therapeutics, Inc. |
Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
|
|
US11219611B2
(en)
|
2015-11-13 |
2022-01-11 |
Ocera Therapeutics, Inc. |
Formulations of L-ornithine phenylacetate
|